December 29, 2017 / 9:15 PM / 5 months ago

BRIEF-Edge Therapeutics Says EG-1962 Phase 3 Study Continues As Planned Following Completion Of Futility Analysis

Dec 29 (Reuters) - Edge Therapeutics Inc:

* EDGE’S EG-1962 PHASE 3 NEWTON 2 STUDY CONTINUES AS PLANNED FOLLOWING COMPLETION OF FUTILITY ANALYSIS

* EDGE THERAPEUTICS - INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDED PHASE 3 NEWTON 2 STUDY OF EG-1962 CONTINUE AS PLANNED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below